Haemopoietic stem-cell transplantation: Recent progress and future promise

Lancet Oncology

Volumn 1, Issue 4, 2000, Pages 227-234

  Craddock, Charles ^a  

^a QUEEN ELIZABETH HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALLOTRANSPLANTATION; AUTOTRANSPLANTATION; BLOOD DISEASE; FEMALE; FORECASTING; GRAFT REJECTION; GRAFT SURVIVAL; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; MALE; METHODOLOGY; PATHOLOGY; PROGNOSIS; REVIEW; RISK ASSESSMENT; RISK FACTOR; STANDARD;

FEMALE; FORECASTING; GRAFT REJECTION; GRAFT SURVIVAL; HEMATOLOGIC NEOPLASMS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; MALE; PROGNOSIS; RISK ASSESSMENT; RISK FACTORS; TRANSPLANTATION CONDITIONING; TRANSPLANTATION, AUTOLOGOUS; TRANSPLANTATION, HOMOLOGOUS;

EID: 0034585908     PISSN: 14702045     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1470-2045(00)00153-4     Document Type: Review

References (43)

1. Uchida N, Aguila H, Fleming W, Weissman I. Rapid and sustained hematopoietic recovery in lethally irradiated mice transplanted with purified Thy-1.1loLin-0Sca+ hematopoietic stem cells. Blood. 83:1994;3758-3779.
2. Dick JE. Human stem cell assays in immune-deficient mice. Curr Opin Hematol. 3:1996;405-409.
3. Bhatia M, Bonnet D, Murdoch B. A newly discovered class of human hematopoietic cells with SCID-repopulating activity. Nat Med. 4:1998;1038-1045.
4. Gandy K, Weissman I. Tolerance of allogeneic heart grafts in mice simultaneously reconstituted with purified allogeneic hematopoietic stem cells. Transplantation. 65:1998;295-304.
5. Schmitz N, Linch DC, Dreger P, et al. Randomised trial of filgrastim-mobilised peripheral blood progenitor cell transplantation versus autologous bone-marrow transplantation in lymphoma patients. Lancet. 347:1996;353-357.
6. Russell NH, Gratwohl A, Schmitz N. Developments in allogeneic peripheral blood progenitor cell transplantation. Br J Haematol. 103:1998;594-600.
7. Papayannopoulou Th, Nakamoto B. Peripheralization of hemopoietic progenitors in primates treated with anti-VLA4 integrin. Proc Nat Acad Sci. 90:1993;9374-9378.
8. Craddock C, Nakamoto B, Andrews R, et al. Antibodies to VLA4 integrin mobilize long-term repopulating cells and augment cytokine-induced mobilization in primates and mice. Blood. 90:1997;4779-4788.
9. Papayannopoulou Th, Craddock C, Nakamoto B, et al. The VLA4/VCAM-1 adhesion pathway defines contrasting mechanisms of lodgement of transplanted murine hemopoietic progenitors between bone marrow and spleen. Proc Natl Acad Sci. 92:1995;9647-9651.
10. Peled A, Petit I, Kollet O, et al. Dependence of human stem cell engraftment and repopulation of NOD/SCID mice on CXCR4. Science. 283:1999;845-848.
11. Yu C, Storb R, Mathey B, et al. DLA-identical bone marrow grafts after low-dose total body irradiation: effects of high dose corticosteroids and cyclosporine on engraftment. Blood. 86:1995;4376-4381.
12. Bacher-Lustig E, Rachamim N, Li N et al. Megadose of T cell-Depleted bone marrow overcomes MHC barriers in sublethally irradiated mice. Nat Med 1995; 1268-1273.
13. Kolb H, Schattenberg A, Goldman J, et al. Graft-Versus-leukemia effect of donor lymphocyte transfusions in marrow grafted patients. European Group for Blood and Marrow Transplantation Working Party Chronic Leukemia. Blood. 86:1995;2041-2050.
14. Mackinnon S, Papadopoulos E, Carabasi M, et al. Adoptive immunotherapy evaluating escalating doses of donor leucocytes for relapse of chronic myeloid leukemia after bone marrow transplantation: separation of graft-versus-leukemia effect from graft-versus-host disease. Blood. 86:1995;1261-1268.
15. Bonnet D, Warren EH, Greenberg PD, et al. CD8(+) minor histocompatibility antigen-specific cytotoxic T lymphocyte clones eliminated human acute myeloid leukemia stem cells. Proc Natl Acad Sci. 96:1999;8639-8644.
16. Tseng LH, Lin MT, Hansen JA, et al. Correlation between disparity for the minor histocompatibility antigen HA-1 and the development of acute graft-versus-host disease after allogeneic marrow transplantation. Blood. 94:1999;2911-2914.
17. Mutis T, Gillespie G, Schrama E, et al. Tetrameric HLAclass 1-minor histocompatibility antigen peptide complexes demonstrate minor histocompatibility antigen-specific cytotoxic T lymphocytes in patients with graft-versus-host-disease. Nat Med. 5:1999;839-842.
18. Hansen J, Gooley T, Martin P, et al. Bone marrow transplants from unrelated donors for patients with chronic myeloid leukemia. N Engl J Med. 338:1998;962-968.
19. Gratwohl A, Hermans J, Goldman J, et al. Risk assessment for patients with chronic myeloid leukaemia before allogeneic bone marrow transplantation. Lancet. 352:1998;1087-1092.
20. Anderson JE, Appelbaum FR, Schoch G, et al. Allogeneic marrow transplantation for refractory anaemia: a comparison of two preparative regimens and analysis of prognostic factors. Blood. 87:1996;51-58.
21. Burnett AK, Goldstone AH, Stevens RM, et al. Randomised comparison of addition of autologous bone-marrow transplantation to intensive chemotherapy for acute myeloid leukaemia in first remission: results of MRC AML 10 trial. UK Medical Research Council Adult and Children's Leukaemia Working Parties. Lancet. 351:1998;700-708.
22. Sierra J, Storer B, Hansen J, et al. Transplantation of marrow cells from unrelated donors for treatment of high-risk acute leukemia: the effect of leukemic burden, donor HLA matching and marrow cell dose. Blood. 89:1997;4226-4235.
23. Gianni AM, Bregni M, Siena S et al. High-dose chemotherapy and autologous bone marrow transplantation comapred with MACOP-B in aggressive B-cell lymphoma. 1997 336: 1290-97.
24. Freedman AS, Neuberg D, Mauch P, et al. Long-term follow-up of autologous bone marrow transplantation in patients with relapsed follicular lymphoma. Blood. 94:1999;3325-3333.
25. Apostolidid J, Gupta RK, Grenzelias D, et al. High-dose therapy with autologous bone marrow support as consolidation of remission in follicular lymphoma: long-term clinical and molecular follow-up. J Clin Oncol. 18:2000;527-536.
26. Khouri I, Keating M, Przepiorka D, et al. Transplant-Lite: induction of graft-versus-malignancy using fludarabine-based nonablative chemotherapy and allogeneic blood progenitor-cell transplantation as treatment for lymphoid malignancies. J Clinical Oncology. 16:1998;2817-2824.
27. Linch DC, Goldstone AH. High-dose therapy for Hodgkin's disease. Br J Haematol. 107:1999;685-690.
28. Russell NH, Miflin G, Stainer C. Allogeneic bone marrow transplantation for multiple myeloma. Blood. 89:1997;2610-2611.
29. Attal M, Harousseau J, Stoppa A, et al. A prospective randomised trial of autologous bone mmarrow transplantation and chemotherapy in multiple myeloma. Intergroupe Francais du Myelome. N Engl J Med. 335:1996;91-97.
30. Rodenhuis S, Richel D, van der Wall E, et al. Randomised trial of high-dose chemotherapy and haemopoietic progenitor-cell support in operable breast cancer with extensive axillary lymph node involvement. Lancet. 352:1998;515-521.
31. Childs RW, Clave E, Tisdale J, et al. Successful treatment of metastatic renal cell carcinoma with a nonmyeloablative allogeneic peripheral-blood progenitor-cell transplant: evidence for a graft-versus-tumor effect. J Clin Oncol. 17:1999;2044-2047.
32. Brenner MK, Rill DR, Moen RC, et al. Gene-marking to trace origin of relapse after autologous bone-marrow transplantation. Lancet. 341:1993;85-86.
33. Gribben JG, Freedman AS, Neuberg D, et al. Immunologic purging of marrow assessed by PCR before autologous bone marrow transplantation for B-cell lymphoma. N Engl J Med. 325:1991;1525-1533.
34. Homberg LA, Boeckh M, Hooper H, et al. Increased incidence of cytomegalovirus disease after autologous CD34-selected peripheral blood stem cell transplantation. Blood. 94:1999;4029-4035.
35. Petersdorf EW, Mickelson EM, Anasetti C, et al. Effect of HLA mismatches on the outcome of hematopoietic transplants. Curr Opin Immunol. 11:1999;521-526.
36. Aversa F, Tabilio A, Cunningham I, et al. Treatment of high-risk acute leukaemia with T-cell-depleted stem cells from related donors with one fully mismatched HLA haplotype. New Engl J Med. 339:1998;1186-1193.
37. Guinan E, Boussiotis V, Neuberg D, et al. Transplantation of anergic histoincompatible bone marrow grafts. N Engl J Med. 340:1999;1704-1714.
38. Clift R, Buckner CD, Appelbaum FR, et al. Allogeneic marrow transplantation in patients with acute myeloid leukameia in first remission: a randomized trial of two irradiation regimens. Blood. 76:1990;1867-1871.
39. Matthews DC, Appelbaum FR, Eary FJ, et al. Phase 1 study of (131) I-anti-CD45 antibody plus cyclophosphamide and total body irradiation for advanced acute leukemia and myelodysplastic syndrome. Blood. 94:1999;1237-1247.
40. Sehn L, Alyea E, Weller E, et al. Comparative outcomes ofT-cell-depleted and non-T-cell-depleted allogeneic bonemarrow transplantation for chronic myelogenous leukaemia: impact of donor lymphocyte infusion. J Clin Oncol. 17:1999;561-568.
41. Slavin S, Nagler A, Naparstek E, et al. Nonmyeloablative stem cell transplantation and cell therapy as an alternative to conventional bone marrow transplantation with lethal cytoreduction for the treatment of malignant and nonmalignant hematologic diseases. Blood. 91:1998;756-763.
42. Giralt S, Estey E, Albitar M, et al. Engraftment of allogeneic hematopoietic progenitor cells with purine analog-containing chemotherapy: harnessing graft-versus-leukemia without myeloablative therapy. Blood. 89:1997;4531-4536.
43. McSweeney P, Shizuru J, Bensinger W, et al. Outpatient PBSC allografts using immunosuppression with low dose TBI before and cyclosporine and mycophenolate mofetil after transplant. Blood. 92:1998;519a.